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Apoptin (apoptosis-inducing protein) harbors tumor-selective characteristics making it a potential safe and effective anticancer
agent. Apoptin becomes phosphorylated and induces apoptosis in a large panel of human tumor but not normal cells. Here, we
used an in vitro oncogenic transformation assay to explore minimal cellular factors required for the activation of apoptin. Flag-
apoptin was introduced into normal ﬁbroblasts together with the transforming SV40 large T antigen (SV40 LT) and SV40 small t
antigen (SV40 ST) antigens. We found that nuclear expression of SV40 ST in normal cells was sufﬁcient to induce
phosphorylation of apoptin. Mutational analysis showed that mutations disrupting the binding of ST to protein phosphatase 2A
(PP2A) counteracted this effect. Knockdown of the ST-interacting PP2A–B56c subunit in normal ﬁbroblasts mimicked the effect
ofnuclearSTexpression,resultingininductionofapoptinphosphorylation.Thesameeffectwasobservedupondownregulation
of the PP2A–B56d subunit, which is targeted by protein kinase A (PKA). Apoptin interacts with the PKA-associating protein
BCA3/AKIP1, and inhibition of PKA in tumor cells by treatment with H89 increased the phosphorylation of apoptin, whereas the
PKA activator cAMP partially reduced it. We infer that inactivation of PP2A, in particular, of the B56c and B56d subunits is a
crucial step in triggering apoptin-induced tumor-selective cell death.
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Tumor formation occurs due to a complex set of processes
roughly based on enhanced survival and limited cell death
activities.
1 Remarkably, a set of viral and cellular proteins has
been found to selectively induce cell death in tumor cells.
2
Among these proteins is the avian virus protein apoptin
(apoptosis-inducingprotein), whichhas beenshown toinduce
p53-independent apoptosis in a broad spectrum of human-
transformed cells.
3 Recent preclinical studies demonstrated
the therapeutic potential of apoptin as a safe and efﬁcient
anticancer agent.
4 Therefore, it is of interest to study the
mechanisms underlying apoptin-induced apoptosis, particu-
larlythe‘switch’responsibleforitsactivationduringoncogenic
transformation.
SV40-T antigens are known to be involved in oncogenic trans-
formation through interference with many cellular processes.
5
Distinct domains on LT that bind and inactivate tumor suppres-
sors p53 and Rb (retinoblastoma protein), have long been known
to have crucial roles in tumor formation.
6 The SV40 small t
antigen (SV40 ST) protein enforces transformation of normal
cells via inhibition of protein phosphatase 2A (PP2A).
7–9
This feature is in accordance with the reduced PP2A levels
found in various human tumor cell types,
10 and accumulating
evidence supporting major tumor suppressive roles for PP2A.
11
Another major cellular regulator implicated in carcinogenesis
is protein kinase A (PKA).
12 Its targets include PP2A,
13 and
for instance, the PKA-interacting protein breast cancer-
associated gene 3 (BCA3) is known to be highly expressed
in breast and prostate cancer cells compared with the normal
surrounding tissue.
14
In this study, we investigated the minimal steps leading to
the activation of apoptin upon malignant transformation. We
previously showed thattransient expression ofthe SV40 large
T antigen (SV40 LT) and SV40 ST antigens in normal human
ﬁbroblasts results in activation of apoptin, displaying all three
of its characteristic features, namely phosphorylation, nuclear
localization and apoptosis.
15 This ﬁnding provided us with an
elegant tool to analyze which domains of the SV40 LT and/or
ST antigens are responsible for this activity. In parallel, BCA3
was identiﬁed as an apoptin-interacting protein, and the
effects of PKA on apoptin phosphorylation were examined.
Analysis of both transformation-related pathways revealed
thatinactivationofPP2Aiscrucialfortheactivationofapoptin.
Results
Transient expression of N-terminal SV40 LT136/ST
activates apoptin in normal human ﬁbroblasts. Apoptin
activity can be induced in normal cells by transient
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15 Hence, we
examined the minimal SV40 domains responsible for this
effect. Expression of the SV40 LT136/ST DNA sequence
results, due to alternative splicing, in two proteins: LT136,
comprising the N-terminal 136 amino acids of LT, and the
entire ST protein, consisting of 174 amino acids (Figure 1a).
16
LT136 contains a DNA J domain, an Rb-binding site and a
nuclear localization signal (NLS). ST shares its DNA J domain
with LT136, but has a unique C-terminal domain encompass-
i n gaP P 2 A - b i n d i n gs i t e .
5
In normal human foreskin ﬁbroblasts, co-transfection of the
SV40 LT136 and ST proteins with Flag-tagged apoptin
Figure 1 Transient expression of N-terminal determinants of SV40 T antigens activates apoptin. (a) Schematic representation of the domains in SV40 LT136/ST. The J
domain (amino acids 1–82) is identical in both LT136 and ST. The Rb-binding domain and NLS in LT136 are also shown. ST is expressed by differential splicing and has a
unique C-terminus, which contains the PP2A-binding domain. (b) Human ﬁbroblasts (F9) were co-transfected with plasmids pcDNA-Flag-apoptin and pcDNA-LT136/ST
(LT136/ST) or pcDNA-neo (neo) by AMAXA nucleofactor transfection. Twenty-four hours post transfection, cells were lysed for western blot analysis with the indicated
antibodies. Mock-transfected F9 cells were used as control. Antibody a-108-P speciﬁcally recognizes phospho-apoptin at its Thr108. Flag-apoptin, LT and ST show the
respective total protein amounts in the transfected cells. Actin was used as loading control. (c–e) Cells were ﬁxed for immunoﬂuorescence analysis at each given time-point
after transfection and then stained with the indicated antibodies by indirect immunoﬂuorescence assay. Scale bar¼20mm
PP2A inactivation triggers apoptin
R Zimmerman et al
2
Cell Death and Diseaseresulted in the latter’s phosphorylation (Figure 1b). Immuno-
ﬂuorescence analysis of F9 cells expressing all three proteins
showed that Flag-apoptin became nuclear already 1 day after
transfection. Nuclear Flag-apoptin was also shown to be
phosphorylated (Figure 1c), and 3 and 5 days post trans-
fection, apoptin was shown to induce apoptosis (Figures 1d
and e). In contrast, F9 ﬁbroblasts expressing apoptin alone
contained mainly cytoplasmic Flag-apoptin, which was, as
expected, not phosphorylated
17,18 and did not induce apop-
tosis (Figures 1c–e).
OurresultsclearlyrevealthattransientexpressionofLT136
and ST proteins in human F9 ﬁbroblasts results in tumor-
selective activation of apoptin, providing us with the possibility
to explore which domains and respective cellular targets of
LT136/ST were responsible for this activity.
Nuclear ST triggers apoptin activation. Next, we examined
whether expression of either LT136 or ST protein alone was
sufﬁcient to activate apoptin phosphorylation. F9 ﬁbroblasts
were co-transfected with plasmids encoding Flag-tagged
apoptin and either one of the following: (a) pcDNA-LT136,
encoding LT136, (b) pcDNA-ST, encoding ST, (c) pcDNA-
LT136/ST, where both LT136 and ST are produced via
alternative splicing, or (d) pcDNA-neo, as a negative control.
In each experiment, activation of apoptin was assayed by
its phosphorylation at position T108, assessed by means of
western blotting. Expression of LT136 alone did not trigger
apoptin phosphorylation, whereas expression of ST clearly
induced apoptin phosphorylation, albeit at a low level (Figure 2).
Co-transfection of Flag-tagged apoptin with ST fused to an
artiﬁcial nuclear localization site (NLS-ST) increased the level of
apoptin phosphorylation signiﬁcantly (Figure 3a).
C103S and P101A point mutations within the PP2A-
binding domain of ST disable activation of apoptin.
Besides its J domain, shared with LT136, ST contains a unique
site for the binding and inactivation of PP2A. This domain has
been shown to contribute to cellular transformation.
5 A single
amino-acid mutation C103S within the ST protein drastically
diminishes the interaction of ST with PP2A (Figure 3c) and its
Figure 2 Nuclear targeting of SV40 ST activates apoptin. In normal human
ﬁbroblasts, apoptin was co-transfected with vector only (Neo), LT136, ST or both
LT136andST.Twenty-fourhoursposttransfection,cellswerelysedforwesternblot
analysis with the antibodies indicated. The relative amount of phosphorylated
apoptin (as compared with the total amount of apoptin) was quantiﬁed and is
indicated below the a-108-P panel. The LT136þST sample was set at 100
Figure 3 Apoptin activation via ST-mediated inhibition of PP2A. (a) pcDNA-Flag-
apoptin was co-transfected with plasmids encoding the indicated proteins or vector
DNA into F9 primary ﬁbroblasts. Western blot assays were performed with the
indicated antibodies at 24h post transfection. (b) F9 primary cells were co-transfected
with pcDNA-Flag-apoptin and plasmids encoding NLS-ST, NLS-ST(P101A), NLS-
ST(C103S) or vector DNA as indicated. Western blot assays were performed with the
indicatedantibodiesat24hposttransfection.Inpanelsaandbthe relativepercentage
ofphosphorylatedapoptininthevarioussampleswasquantiﬁedandisindicatedbelow
the a-108-P panel c. PP2A binding to ST isabolished by C103S mutation. LT136 and
ST with or without the C103S mutation (LT136/ST or LT136/ST(C103S) were fused
withaStrep-tagattheirNterminus.Celllysateswerepreparedat24hposttransfection
for protein–protein interaction assays as indicated in Materials and Methods. The ﬁnal
elutions wereanalyzedbywesternblotwithantibodiesagainst PP2Aasubunit, LTand
ST, respectively. Actinwas taken as equal loading control. The ﬁrst lane (input control)
indicated total amount of endogenous proteins in cell lysates
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19 Therefore, we studied the effect of
the C103S mutation within the PP2A-binding site on the
activation of apoptin by (nuclear) ST in normal human cells.
F9 cells were analyzed for phosphorylation of Flag-apoptin
upon co-expression with ST, NLS-ST or NLS-ST(C103S)
protein. Figure 3b shows that expression of NLS-ST clearly
induced apoptin phosphorylation. Introduction of the NLS-
ST(C103S) mutation abolished this induction, although
apoptin protein was expressed at a similar level. Similar
results were obtained with the NLS-ST-(P101A) mutant
(Figure 3b). The P101A point mutation within ST is also
known to disturb the ST–PP2A interaction and transforming
capacity of ST.
19 These results suggest that ST interaction
with PP2A is crucial to apoptin activation, and that inactivation
of PP2A by ST might be sufﬁcient to activate apoptin.
Knockdown of PP2A B56g via RNA interference (RNAi)
activates apoptin phosphorylation in normal human
ﬁbroblasts. Two independent studies reported that ST
interaction with PP2A resulted in the inhibition of the B56g
regulatory subunit, resulting in cellular transformation.
8,9
Therefore, we examined whether downregulation of B56g
via RNAi could trigger phosphorylation of apoptin in normal
cells. Our shRNA sequence was veriﬁed to reduce ectopic
expression of B56g (Figure 4a). Normal F9 ﬁbroblasts co-
expressing both apoptin and shRNA directed against B56g
mRNA manifested a clear level of phosphorylated apoptin in
comparison with the cells transfected with apoptin and the
RNAi control vector (Figure 4c). Our data thus indicate that
inhibition of the PP2A–B56g subunit is a crucial and sufﬁcient
step for apoptin activation.
Overexpression of PKA-interacting protein BCA3 stimu-
lates apoptin activity in tumor cells. Analogous to the
enhancing effect of ST on apoptin phosphorylation in normal
cells, we observed an enhancement of apoptin phosphoryla-
tion in tumor cells by BCA3. BCA3 was identiﬁed as an
apoptin-interacting protein by means of a yeast two-hybrid
assay, and interacts with apoptin in a human cellular
background (Figure 5a). Co-expression of BCA3 and Flag-
apoptin in human Saos-2 tumor cells resulted in a signiﬁcant
increase in the apoptosis activity of apoptin (Figure 5b). In
fact, as early as 6h after transfection, phosphorylated
apoptin could readily be detected in Saos-2 cells expressing
both apoptin and BCA3, whereas in cells expressing apoptin
alone (control) apoptin phosphorylation was not yet visible at
this early time-point (Figure 5c).
As BCA3
11 has been shown to interact with the catalytic
subunit of PKA,
20 the involvement of PKA in apoptin
phosphorylation was investigated. Treatment of Saos-2 cells
with H89, a known PKA inhibitor,
21 enhanced apoptin
phosphorylation. In contrast, addition of the PKA activator
cAMP
22 diminished apoptin phosphorylation (Figure 5d).
These results suggest that interference with PKA activity
favors activation of apoptin. By taking into account the fact
that the B56d subunit of PP2A has been shown to be targeted
by PKA,
23 we proved that this is also the case in our cellular
system. Indeed, H89 treatment of Saos-2 cells decreased the
level of active serine-phosphorylated B56d, whereas cAMP
enhanced the amount of active B56d (Figures 5e–g).
Downregulation of PP2A–B56d subunit activates apoptin
phosphorylation in normal cells. The experiments
described above indicate that in cancer cells an inverse
relation exists between the activity of PP2A–B56d, as judged
by its phosphorylation,
23 and the potential of apoptin to
become phosphorylated in the same cells. For this reason, it
was interesting to examine whether inhibition of the expres-
sion of the PP2A–B56d subunit in human F9 cells would
positively affect the phosphorylation of apoptin. Downregula-
tion of B56d protein expression through RNAi was conﬁrmed
in normal F9 ﬁbroblasts (Figure 4b). Co-expression of shRNA
targeting B56d mRNA together with apoptin in normal F9
cells clearly resulted in the activation of apoptin phosphor-
ylation, as compared with F9 cells transfected with apoptin
and the RNAi control vector (Figure 4c).
In conclusion, our results imply that PP2A complexes
containing the regulatory subunits B56 d and g are essential
formaintaining a normal cell environment, as the loss of either
one of these subunits results in the activation of apoptin.
Discussion
Activationoftumor-selectiveapoptosis-inducingproteinsisan
intriguing phenomenon and revealing the molecular switch
behind this process could allow important insights for
developing anticancer therapies. Apoptin was the ﬁrst protein
known to harbor apoptosis activity selectively in transformed
Figure4 KnockdownofPP2A–B56gandB56dsubunitstriggersapoptinphosphorylationinnormalcells.(a)DownregulationofPP2A–B56gsubunitbyshRNA.HeLacells
were co-transfected with pCEP-4HA-B56g expressing 4HA-tagged B56g, and either shB56g or control pSuper vector and lysed 48h post transfection, followed by western
blotting analysis with the indicated antibodies. (b) Downregulation of PP2A–B56d subunit by shRNA. F9 cells were transfected with pSuper vector encoding shRNA directed
against PP2A–B56d or pSuper vector control; 24h post transfection, cell lysates were prepared and subsequently analyzed by western blot. (c) F9 cells were co-transfected
withFlag-apoptinandeitherpSupervectorencodingshRNAdirectedagainstPP2A–B56g,dorcontrol;24–48hposttransfection,celllysateswerepreparedandsubsequently
analyzed by western blot
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2 However, the molecular mechanisms under-
lying apoptin’s tumor-selective activity are largely unknown.
4
Our studies revealed that interference with the normal
function of PP2A is sufﬁcient to activate apoptin in a tumor-
selective fashion. This is inferred from two independent lines
of research.
In one study, we examined the effect of speciﬁc domains
within the transforming SV40 proteins LT136 and ST on the
activation of apoptin. The C-terminal PP2A-binding and
transformationdomainofST,
5,24whentargetedtothenucleus
of normal cells, turned out to be crucial for the tumor-
characteristic activation of apoptin. We showed that both
C103S and P101A point mutations within the ST PP2A-
binding site
25 abrogated the phosphorylation of apoptin
induced by NLS-ST in normal human ﬁbroblasts. RNAi
studies conﬁrmed that inactivation of the B56g protein
promotes phosphorylation of apoptin in human ﬁbroblasts.
We have previously shown
15 that the N-terminal J domain,
which is commonto both LTand ST (see Figure 1), isinvolved
in apoptinactivation.Interestingly, sincethe completionofthis
work two independent groups have resolved the molecular
structure of the SV40 ST complex with PP2A and shown that
both the C-terminal PP2A-binding domain and the N-terminal
J domain are in direct contact with the A subunit of PP2A.
8,9
The structure provides a mechanism how binding of ST to the
A subunit of PP2A displaces the B56g subunit and as such
inactivates PP2A. The results described in Supplementary
FigureS1(SupplementaryInformation)indicatethatalsotheJ
domain (either present on LT or ST) needs to be functional in
order to activate apoptin in combination with a functional
C-terminal PP2A-binding site on ST. The data strongly
suggest that the J domain of LT can also contribute to the
displacement of B56g and the activation of apoptin in concert
with our previous conclusions. However, the contribution of
ST, which has not been analyzed in detail in the previous
study, is essential for activating apoptin (Figure 2).
A second line of research indicated that interference with
the PP2A–B56d subunit also led to the activation of apoptin.
Figure 5 BCA3 interacts with apoptin and stimulates its activity. (a) Apoptin
interacts with BCA3 in a cellular background. Normal human foreskin ﬁbroblasts
were transfected with plasmids encoding myc-tagged BCA3 and Flag-tagged
apoptin,orcontrolplasmidin theindicatedcombinations. Totallysates(L) orprotein
complexes immunoprecipitated (IP) with antibody against the myc- (left panel) or
Flag-tags(rightpanel)wereseparatedbySDS-PAGEandanalyzedbywesternblot.
(b) Expression of myc-BCA3 together with Flag-apoptin results in increased
induction of apoptosis. Human Saos-2 tumor cells were transfected with plasmids
encoding Flag-tagged apoptin and myc-tagged BCA3, or vector control in the
indicated combinations and grown on glass coverslips. Forty-eight hours post
transfection, slides were ﬁxed and stained with appropriate antibodies for
immunoﬂuorescence analysis. pMaxGFP (Amaxa) was used as a negative control.
Apoptosis was assessed according to characteristic morphological changes
35
following DAPI staining as shown in ﬁgure 1. Data are representative of three
independent experiments, in which at least 100 cells were scored. (c) Co-
expression of myc-BCA3 enhances apoptin phosphorylation. Saos-2 cells
transfected with BCA3 and apoptin, or apoptin alone, were lysed 6h post
transfection and analyzed for apoptin phosphorylation by western blot analysis. (d)
Inhibition of PKA results in increased apoptin phosphorylation. Saos-2 cells were
transfected with Flag-tagged apoptin, and treated with the PKA inhibitor H89 (1h,
10mM)oractivatorcAMP(30min,10mMH89,followedby30min1mMcAMP)24h
post transfection. Cells were then lysed and their contents analyzed by western blot
usingindicatedantibodies.Therelativepercentageofphosphorylatedapoptininthe
various samples was quantiﬁed and is indicated below the a-108-P panel. (e) Effect
of PKA inhibitors/inducers on PP2A–B56d phosphorylation. In a ﬁrst instance,
phosphorylated proteins were immunoprecipitated from Saos-2 whole-cell lysate
(WCL) with six different antibodies directed against phosphoserines, as described
(MaterialsandMethods).WesternblotwasperformedwithantibodiesagainstB56d.
The light chain signal shows equal assay conditions. Note that only antibody 5
detects phospho- B56d.( f) Saos-2 cells were treated with PKA inhibitor H89 or
mock-treated and immunoprecipitated with the phosphoserine antibody 5 (see
panel e). The amount of pulled-down B56d was determined by western blot using
an antibody directed against B56d and quantiﬁed. The amount of phospho B56d
in the mock-treated cells was set at 100. (g) Saos-2 cells were treated with PKA-
stimulator cAMP or mock-treated and immunoprecipitated with antibodies against
B56d. The amount of phosphorylated B56d was determined by western blot
using the phosphoserine antibody 5 (panel e) and quantiﬁed. The amount of
phosphoB56d in the mock-treated cells was set at 100
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PKA activator or inhibitor. PKA is known to phosphorylate the
B56d subunit of PP2A leading to increased PP2A activity.
23
Ectopic expression of the apoptin- and PKA-interacting
protein BCA3, or inhibition of PKA by treatment with H89
both resulted in enhanced phosphorylation and apoptosis
activity of apoptin in human cancer cells. Stimulation of PKA
by cAMP resulted in enhanced phosphorylation of PP2A–
B56d and a lower level of phosphorylated apoptin in Saos-2
tumor cells. On the contrary, H89 decreased the level of
phosphorylated B56d in tumor cells and enhanced apoptin
phosphorylation. These data indicate that derailed PP2A
activity is crucial for activating apoptin in accordance with the
data obtained in our SV40 transformation assay. This vision
was further highlighted by RNAi studies, showing that
inhibition of the expression of PP2A–B56d activated apoptin
even in normal human cells.
Our studies reveal that apoptin senses PP2A inactivation
during malignant transformation. Interestingly, the d and g
subunits are the only nuclear PP2A–B56 subunits,
25 and
nuclear localization is important for both SV40-T antigen-
induced cell transformation
5 and apoptin-induced tumor-
selective apoptosis.
3 PP2A complexes containing B56d
domains prevent entry of cells into mitosis upon DNA
damage.
26 B56g is also known to mediate dephosphorylation
and stabilization of the tumor suppressor protein p53 upon
DNA damage, inhibiting cellular proliferation and transforma-
tion.
27 Evidence has been provided that derailment of B56g
results in aberrancies in functioning of, for example, cell cycle
and tumor suppressor proteins resulting in cell transforma-
tion.
10,25 Many of these features are likely due to the fact that
PP2A–B56 subunits have an essential role in the stabilization
of chromosome–spindle interactions during normal cell
division.
28 In this respect, it is interesting to mention that
inhibition of Bub1, another mitotic regulator, results in nuclear
translocation of apoptin in normal cells.
29 Apparently, apoptin
can sense aberrant mitosis and the ensuing genetic instabil-
ity
30 or DNA-damage response signaling.
29
PP2A has also a role in the activation of other tumor-
selective apoptosis-inducing proteins. Besides apoptin, the
adenovirus E4orf4 protein has been demonstrated to selec-
tively induce apoptosis in human cancer cells. Direct interac-
tion of E4orf4 with PP2A regulatory B domains is essential for
the tumor-selective apoptosis activity of E4orf4. Interaction of
E4orf4 with PP2A–B55 results in downregulation of myc
oncogene expression.
31 In addition to SV40 ST, other viral-
transforming proteins also interact with PP2A, further accent-
uating its relevance in cellular transformation.
32
Further steps within the development of tumorigenic cells
seem at least not critical for apoptin’s tumor-selective
apoptosis characteristics. These conclusions are in accor-
dance with the observations by others and ourselves that
apoptin is able to induce apoptosis in a very broad panel of
tumor types.
3,4,33 If one assumes that tumor cells arise by a
wide variety of mechanisms, all the while sharing a limited
number of key characteristics,
34 then apoptin simply needs to
recognize one (or a subset) of these characteristics.
Insummary,ourresultsshowthatinactivationofthenuclear
PP2A–B56 d and/or g subunits are sufﬁcient to trigger
apoptin’s tumor-selective apoptosis activity. PP2A provides
a central phosphatase activity affecting many cellular signal-
ing pathways. As derailment of PP2A activity is increasingly
linked to oncogenic transformation, the sensing of such a
central regulator by apoptin might provide a rationale for its
efﬁcient killing of tumor cells arising from a wide range of
different origins.
Materials and Methods
Cells and cell culture. Human diploid foreskin F9 ﬁbroblasts, isolated from
neonatal foreskin, were obtained in the late 1980s from Dr. M Ponec (Department
of Dermatology, Leiden University Medical Center). Cells were batch-frozen after
careful morphological inspection. At subsequent passages cells were regularly
screened for their typical ﬁbroblast-like morphological appearance. All cells used
were below passage 15 and cultured in Dulbecco’s modiﬁed Eagle’s medium
containing 10% newborn calf serum, 100U/ml penicillin and 100mg/ml strepto-
mycin (Invitrogen, Breda, The Netherlands). The human Saos-2 osteosarcoma
and the HeLa cervical carcinoma cell lines were purchased from the American
Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in the same
medium as mentioned above. Cultures were regularly tested to ensure the
absence of Mycoplasma infection. Cell morphology was regularly monitored to
control the absence of cross-contamination. The sensitivity to apoptin is
characteristic of the various cell types used and is regularly assessed (see below).
DNA plasmids. The DNA sequence encoding apoptin was synthesized by
BaseClear (Leiden, The Netherlands) according to the apoptin sequence used by
Danen-Van Oorschot et al.,
35 and cloned into the mammalian expression vector
pcDNA3.1(þ) (Invitrogen). The oligonucleotide fragment encoding the Flag-tag
(Invitrogen) was inserted to create the pcDNA-Flag-apoptin plasmid encoding
apoptin fused with a Flag-tag at its N terminus.
Plasmid pRSV-TN136encoding theﬁrst 136 N-terminalamino acids of SV40 LT,
including the region coding for SV40 ST, was a kind gift from Dr. JM Pipas
(Department of Biological Sciences, University of Pittsburgh, Pittsburgh, PA, USA).
From pRSV-TN136, we generated the pcDNA-LT136/ST plasmid, which encodes
the LT136 (the N-terminally truncated LT fragment containing the ﬁrst 1–136 amino
acids) and full-length ST. pcDNA-LT136, encoding LT136 only, was constructed by
introducing an intron deletion disabling ST expression.
36
pcDNA expression vectors encoding only ST sequences were derived from
pRSV-ST, pcDNA-ST encodes for ST; pcDNA-NLS-ST contains an ST fused to a
NLS-ST and pcDNA-NLS-ST(C103S) and NLS-ST(P101A) mutants encode the
N-terminal NLS-ST fusion protein containing, respectively, the C103S or P101A
mutation within the PP2A-binding site.
37
The sequences encoding the N-terminal 136 amino acids of LT together with
either full-length ST or the C103S ST-mutant were cloned into pEXPR-IBA105
vector to generate pEXPR-IBA105-LT136/ST and pEXPR-IBA105-LT136/STC103S,
respectively. These plasmids expressed Strep-tagged LT136/ST or LT136/ST-C103S
proteins enabling interaction studies with PP2A (see below).
38 pCEP-4HA-B56g,
encoding 4HA-tagged B56g, was a kind gift from Dr. M Mumby (University of
Texas, TX, USA).
Apoptin-interacting partners were obtained by yeast two-hybrid screening
and veriﬁed by immunoprecipitation assays in mammalian cells, as previously
described by Danen-Van Oorschot et al.
35 Positive clones from the yeast two-
hybridscreen weredigestedwith XhoI to generate cDNA fragments, and subcloned
into pMT2SM-myc to provide the fragments with an in-frame N-terminal myc-tag.
The cDNA fragment encoding BCA3, including the myc-tag, was subsequently
cloned into pcDNA.
Transfection methods. We used transfection reagent DOTAP (N-(1-(2,3-
dioleoyloxy)propyl)-N,N,N-trimethylammonium methylsulfate)
35 or AMAXA nucleo-
fection technology in conjunction with cell-type-speciﬁc NucleofectorTM solution
(Lonza, Cologne, Germany)
39 for DNA delivery into cells. When co-transfection
or triple-transfection was performed, the ratio of each plasmid was 1:1 or 1:1:1
(in micrograms). In addition to the analysis by western blot, the cells were seeded
on several glass coverslips to allow parallel analysis at the single-cell level by
immunoﬂuorescence assay.
Western blot analysis. Cells were lysed directly in Laemmli buffer
(2% SDS, 10% glycerol, 60mM Tris-Cl (pH 6.8), 2% b-mercaptoethanol,
0.002% bromophenol blue). Cell lysates were separated by SDS-polyacrylamide
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membranes (Bio-Rad, Hercules, CA, USA). Blots were then incubated with
antibodies against phosphorylated apoptin (a-108-P;
15), Flag-apoptin (a-Flag M2,
Sigma-Aldrich, St. Louis, MO, USA), SV40 LT (PAb416, Pab419, Calbiochem/
Merck, Darmstadt, Germany ), SV40 ST (Pab280, Calbiochem/Merck), PP2A Aa
(C-20, Santa Cruz, Heidelberg, Germany), PP2A–B56g (a-B56g, kind gift
from Dr. Marc Mumby, Health Science Center, University of Texas, TX, USA),
PP2A–B56d (a-B56d, Santa Cruz), myc-tagged BCA3 (a-myc, BD Biosciences,
Franklin Lakes, NJ, USA) and actin (a-actin, Santa Cruz). Antibodies directed
against phosphorylated serine were 1C8 (1), 4A3 (2), 4A9 (3), 4H4 (4), 7F12 (5)
and 16B4 (6); they recognize phosphoserine with various efﬁciencies depending
on the surrounding amino-acid motif (Enzo Life Sciences, Antwerp, Belgium).
Horseradish peroxidase-conjugated goat antibody against rabbit or mouse
immunoglobulin G, or rabbit antibody against goat immunoglobulin G (Sigma-
Aldrich) was used as secondary antibody for signal detection by enhanced
chemiluminescence. Films were quantiﬁed using Quantity One Analysis Software
(Bio-Rad).
Protein interaction assays. Detection of a possible interaction of ST or
ST-C103S mutant protein with PP2A in human HeLa cells was performed as
follows. Twenty-four hours after DNA transfection, cells were washed twice with
phosphate-buffered saline and harvested in ice-cold mild lysis buffer (50mM Tris
(pH 7.5), 5mM EDTA, 250mM NaCl, 0.1% Triton X-100, 5mM NaF, 1mM
Na3VO4, 20mM beta-glycerolphosphate, and Protease Inhibitor Cocktail (Roche,
Basel, Switzerland), followed by incubation on ice for 30min. The supernatant of
the lysates was prepared by centrifugation at 13000 g and 41C for 30min.
Strep-tagged proteins and their interacting proteins were captured using the One-
strep kit (IBA, Go ¨ttingen, Germany) according to the manufacturer’s protocol, and
resolved on SDS-PAGE, followed by western blotting analysis with appropriate
antibodies.
RNAi assay. For human PP2A–B56g, the target sequence was: 50-GATGAA
CCAACGTTAGAAG-30; for the PP2A– B56d two sequences were targeted
(1) 50-GTGTGTCTCTAGCCCCCAT-30 and (2) 50-GACCATTTTGCATCGCATC-30
(data not shown). The pSUPER vector was designated for shRNA plasmid
constructions.
40 The ampliﬁcation and puriﬁcation of plasmids were performed
as speciﬁed by manufacturer’s instruction (GeneService, Cambridge, UK). Cells
transfected with shRNA plasmids were lysed at 24–48h after transfection, and
then analyzed by western blot assay as described above.
Immunoﬂuorescence assay. Cells were grown on glass coverslips.
At indicated time points after transfection, coverslips were ﬁrst washed once with
phosphate-buffered saline, and subsequently ﬁxed with methanol/acetone (50%/
50%) for 5–10min at room temperature. After air-drying, the slides were used for
immunocytochemical staining or stored at  201C for further analysis.
Immunocytochemical staining was carried out as described by Danen-Van
Oorschot et al.
35 The following antibodies were used: a-108-P, a rabbit polyclonal
antibody recognizing phosphorylated apoptin at T108 and a-Flag, a mouse
monoclonal antibody recognizing Flag-apoptin. SV40 proteins were visualized with
PAb416, a mouse monoclonal antibody recognizing the epitope residing in amino
acids 83–128 of LT and non-reactive with ST or PAb280, a mouse monoclonal
antibody against the C terminus of ST. The ﬂuorescein isothiocyanate or
rhodamine-conjugated goat antibodies (Jackson ImmunoResearch Laboratories,
Newmarket, UK) were used as secondary antibodies. Nuclei were stained with
2,4-diamidino-2-phenylindole (DAPI) and apoptosis was assessed according to
characteristic morphological changes.
35
PKA inhibition and stimulation. Saos-2 cells were transfected with
pcDNA-Flag-apoptin and incubated 24h post transfection with 10mM H89 (Merck
Millipore, Billerica, MA, USA) for 1h (PKA inhibition), or 30min with H89 followed
by incubation with 1mM cAMP (Sigma-Aldrich) for another 30min (PKA
stimulation). Cells were then lysed in Laemmli buffer and the cell lysates
analyzed for apoptin phosphorylation by western blotting. To determine the
phosphorylation status of B56d, cells were lysed after treatment in mild lysis buffer
as described for the protein interaction assay with addition of PhosSTOP (Roche).
After 30min of incubation, cell lysate was obtained by 15min of centrifugation at
16100 rcf at 41C. Whole-cell lysate was incubated 1.5h with antibody either
against B56d or against phosphorylated serines. mMACS microbeads (Miltenyi
Biotech, Bergisch Gladbach, Germany) were added for 1h and proteins were
pulled down using the mMACS column system according to the manufacturer’s
protocol. Elution was performed using Laemmli buffer, and proteins were
resolved on SDS-PAGE, followed by western blotting analysis with appropriate
antibodies.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements. We thank Dr. James Pipas, University of Pittsburg, and
Dr. Marc Mumby, University of Texas for their kind gifts and Dr. Maarten de Smit,
Leiden University for advice. This work was supported by a grant from the Dutch
Royal Society of Arts and Sciences (06CDP010).
1. Wenner CE. Cell signaling and cancer-possible targets for therapy. J Cell Physiol 2010;
223: 299–308.
2. BrunoP,BrinkmanCR,BoulangerM-C,FlintermanM,KlanritP,LandryMCetal.Familyat
last: highlights of the ﬁrst international meeting on proteins killing tumour cells. Cell Death
Diff 2009; 16: 184–186.
3. BackendorfC,VisserAE,DeBoerAG,ZimmermanR,VisserM,VoskampPetal.Apoptin:
therapeutic potential of an early sensor of carcinogenic transformation. Annu Rev
Pharmacol Toxicol 2008; 48: 43–69.
4. GrimmS.NotebornMHM.Anticancergenes:inducersoftumour-speciﬁccelldeath.Trends
Mol Med 2010; 16: 88–96.
5. Pipas J. SV40: cell transformation and tumorigenesis. Virology 2009; 384: 294–303.
6. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Mary W, Brooks MW,
Weinberg RA. Creation of human tumour cells with deﬁned genetic elements. Nature
1999; 400: 464–468.
7. Sablina AA, Hector M, Colpaert N, Hahn WC. SV40 small antigen and PP2A phosphatase
in cell transformation. Cancer Res 2008; 70: 10474–10484.
8. Chen Y, Xu Y, Bao Q, Xing Y, Li Z, Lin Z et al. Structural and biochemical insights into the
regulation of protein phosphatase 2A by small t antigen of SV40. Nat Struc Mol Biol 2007;
6: 527–534.
9. Cho US, Morrone S, Sablina AA, Arroyo JD, Hahn WC, Xu W. Structural basis of PP2A
inhibition by small T antigen. PLoS Biol 2007; 5: e202.
10. Sablina AA, Hahn WC. SV40 small T antigen and PP2A phosphatase in cell
transformation. Cancer Metastasis Rev 2008; 27: 137–146.
11. Westermarck J, Hahn W. Multiple pathways regulated by the tumor suppressor PP2A in
transformation. Trends Mol Med 2008; 14: 152–160.
12. NaviglioS,CaragliaM,AbbruzzeseA,ChiosiE,DiGestoD,MarraMetal.ProteinkinaseA
as a biological target in cancer therapy. Expert Opin Ther Targets 2009; 13: 83–92.
13. Usui H, Inoue R, Tanabe O, Nishito Y, Shimizu M, Hayashi H et al. Activation of protein
phosphatase 2A by cAMP-dependent protein kinase-catalyzed phosphorylation of the 74-
kDa B00 (delta) regulatory subunit in vitro and identiﬁcation of the phosphorylation sites.
FEBS Lett 1998; 430: 312–316.
14. Kitching R, Li H, Wong MJ, Kanaganayakam S, Kahn H, Seth A. Characterization of a
novel human breast cancer associated gene (BCA3) encoding an alternative spliced
proline-rich protein. Biochim Biophys Acta 2003; 1625: 116–121.
15. Zhang Y-H, Kooistra K, Pietersen AM, Rohn JL. Noteborn MHM. Activation of the tumor-
speciﬁc death effector apoptin and its kinase by an N-terminal determinant of simian virus
40 large T antigen. J Virol 2004; 78: 9965–9976.
16. SrinivasanA, McClellan AJ,Vartikar J,MarksI, Cantalupo P,Li Yetal. Theamino-terminal
transforming region ofsimian virus 40 large Tand small t antigens functions as a Jdomain.
Mol Cell Biol 1997; 17: 4761–4773.
17. Rohn JL, Noteborn MHM. The viral death effector apoptin reveals tumor-speciﬁc
processes. Apoptosis 2004; 9: 315–322.
18. Alvisi G, Poon IK, Jans DA. Tumor-speciﬁc nuclear targeting: promises for anti-cancer
therapy. Drug Resist Update 2006; 9: 40–50.
19. Mungre S, Enderle K, Turk B, Porras A, Wu Y-Q, Mumby MC et al. Mutations which affect
the inhibition ofprotein phosphatase 2A by simian virus 40small-tantigen in vitrodecrease
viral transformation. J Virol 1994; 68: 1675–1681.
20. SastriM,BarracloughDM,CarmichaelPT,TaylorSS.Akinase-interactingproteinlocalizes
protein kinase A in the nucleus. Proc Natl Acad Sci USA 2005; 102: 349–354.
21. LochnerA,Moolman JA.ThemanyfacesofH89:areview.CardiovascDrugRev2006;24:
261–274.
22. Bulun SE, Simpson ER. Aromatase expression in women’s cancers. Adv Exp Med Biol
2008; 630: 112–132.
23. Ahn J-H, McAvoy T, Rakhilin SV, Nishi A, Greengard P, Naim AC. Protein kinase A
activates protein phosphatase 2A by phosphorylation of the B56d subunit. Proc Natl Acad
Sci USA 2007; 104: 2979–2984.
24. Arroyo JD, Hahn WC. Involvement of PP2A in viral and cellular transformation. Oncogene
2005; 24: 7746–7755.
PP2A inactivation triggers apoptin
R Zimmerman et al
7
Cell Death and Disease25. Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, Hahn WC. Identiﬁcation
of speciﬁc PP2A complexes involved in human cell transformation. Cancer Cell 2004; 5:
127–136.
26. Virshup DM, Shenolikar S. From promiscuity to precision: protein phosphatases get a
makeover. Mol Cell 2009; 33: 537–545.
27. Li H, Cai X, Shouse GP, Piluso LG, Liu X. A speciﬁc PP2A regulatory subunit, B56gamma,
mediates DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J 2007; 26:
402–411.
28. Foley EA, Maldonado M, Kapoor TM. Formation of stable attachments between
kinetochores and microtubules depends on the B56-PP2A phosphatase. Nat Cell Biol
2011; 10: 1265–1271.
29. Kucharski TJ, Gamache I, Gjoerup O, Teodoro JG. DNA damage response signaling
triggers nuclear localization of the chicken anemia virus protein Apoptin. J Virol 2011; 85:
12638–12649.
30. Pihan GA, Doxsey SJ. The mitotic machinery as a source of genetic instability in cancer.
Semin Cancer Biol 1999; 4: 289–302.
31. Ben-IsraelH,SharfR,RechaviG,KleinbergerT.AdenovirusE4orf4proteindownregulates
Myc expression through interaction with PP2A-B55 subunit. J Virol 2008; 82: 9381–9388.
32. Zhao RY, Elder RT. Viral infections and cell cycle G2/M regulation. Cell Res 2005; 115:
143–149.
33. Maddika S, Mendosa FJ, Hauff K, Zamzow CR, Paranjothy T, Los M. Cancer-selective
therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther 2006; 5: 10–19.
34. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:
646–674.
35. AAAM Danen-Van Oorschot, Voskamp P, MCMJ Seelen, MHAM Miltenburg, Bolk MW,
Tait SW et al. Human death effector domain-associated factor interacts with the viral
apoptosis agonist apoptin and exerts tumor-preferential cell killing. Cell Death Differ 2004;
11: 564–573.
36. Yamashita K, Ikenaka Y, Kakutani T, Kawaharada H, Watanabe K. Comparison of human
lymphotoxin gene expression in CHO cells directed by genomic DNA or cDNA sequences.
Agric Biol Chem 1990; 54: 2801–2809.
37. Gjoerup O, Zaveri D, Roberts TM. Induction of p53-independent apoptosis by simian 40
small t antigen. J Virol 2001; 75: 142–155.
38. Schmidt TGM, Skerra A. The Strep-tag system for one-strep puriﬁcation and high-afﬁnity
detection or capturing of proteins. Nature Protoc 2007; 2: 1528–1535.
39. Rohn JL, Zhang Y-H, RIJM Aalbers, Otto N, Den Hertog J, Henriquez NV et al. A tumor-
speciﬁc kinase activity regulates the viral death protein apoptin. J Biol Chem 2002; 277:
50820–50827.
40. Boutros M, Ahringer J. The art and design of genetic screens: RNA interference. Nat Rev
Genet 2008; 9: 554–566.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This work is
licensed under the CreativeCommons Attribution-NonCommercial-No
DerivativeWorks3.0Unported License. To viewacopyofthis license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies the paper on Cell Death and Disease website (http://www.nature.com/cddis)
PP2A inactivation triggers apoptin
R Zimmerman et al
8
Cell Death and Disease